Abstract
Here we review current literature on genetic and signaling pathway regulators of tumor initiating cells in prostate cancer. While we emphasize the consequence of PTEN loss and PI3K/AKT activation in prostate cancer initiating cells, we also assess the importance of other signaling regulators, including RAS/MAPK, WNT/b-catenin, MYC, NKX3.1 and p53 on these cells.Importantly, we stress how these factors alone, or in collaboration, alter tumor initiating cell/cancer stem cell function and consequently, phenotypes in in vivo prostate cancer models.Our review also highlights the understanding of how genetic pathway alteration influences cancer initiation by way of lineage tracing or cell type specific disruption.Functional similarities and differences of how tumor suppressor loss impacts human prostate cancer are also addressed, where appropriate.Finally, we touch on outstanding questions that future experimentation will hopefully address.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Abou-Kheir WG et al (2010) Characterizing the contribution of stem/progenitor cells to tumorigenesis in the Pten−/−TP53−/− prostate cancer model. Stem Cells 28(12):2129–2140
Ahuja D, Saenz-Robles MT, Pipas JM (2005) SV40 large T antigen targets multiple cellular Âpathways to elicit cellular transformation. Oncogene 24(52):7729–7745
Backman SA et al (2004) Early onset of neoplasia in the prostate and skin of mice with Âtissue-Âspecific deletion of Pten. Proc Natl Acad Sci USA 101(6):1725–1730
Barbieri CE et al (2012) Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 44(6):685–689
Bhatia B et al (2008) Critical and distinct roles of p16 and telomerase in regulating the proliferative life span of normal human prostate epithelial progenitor cells. J Biol Chem 283(41): 27957–27972
Bisson I, Prowse DM (2009) WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res 19(6):683–697
Cao Q et al (2008) Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 27(58):7274–7284
Chen Z et al (2005) Crucial role of p53-dependent cellular senescence in suppression of Pten-Âdeficient tumorigenesis. Nature 436(7051):725–730
Choi N et al (2012) Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation. Cancer Cell 21(2):253–265
Cicalese A et al (2009) The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell 138(6):1083–1095
Clevers H, Nusse R (2012) Wnt/beta-catenin signaling and disease. Cell 149(6):1192–1205
Collins AT et al (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65(23):10946–10951
Dubey P et al (2001) Alternative pathways to prostate carcinoma activate prostate stem cell antigen expression. Cancer Res 61(8):3256–3261
Dubrovska A et al (2009) The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci USA 106(1):268–273
Ellwood-Yen K et al (2003) Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4(3):223–238
Fan C et al (2009) PTEN inhibits BMI1 function independently of its phosphatase activity. Mol Cancer 8:98
Gerstein AV et al (2002) APC/CTNNB1 (beta-catenin) pathway alterations in human prostate cancers. Genes Chromosomes Cancer 34(1):9–16
Gingrich JR, Greenberg NM (1996) A transgenic mouse prostate cancer model. Toxicol Pathol 24(4):502–504
Glinsky GV, Berezovska O, Glinskii AB (2005) Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 115(6):1503–1521
Goldstein AS et al (2008) Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics. Proc Natl Acad Sci USA 105(52):20882–20887
Goldstein AS et al (2010) Identification of a cell of origin for human prostate cancer. Science 329(5991):568–571
Goto K et al (2006) Proximal prostatic stem cells are programmed to regenerate a proximal-distal ductal axis. Stem Cells 24(8):1859–1868
Grasso CS et al (2012) The mutational landscape of lethal castration-resistant prostate cancer. Nature 487(7406):239–243
Greenberg NM et al (1995) Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 92(8):3439–3443
Groszer M et al (2001) Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science 294(5549):2186–2189
Groszer M et al (2006) PTEN negatively regulates neural stem cell self-renewal by modulating G0-G1 cell cycle entry. Proc Natl Acad Sci USA 103(1):111–116
Grubb RL 3rd, Kibel AS (2007) Prostate cancer: screening, diagnosis and management in 2007. Mo Med 104(5):408–413; quiz 413–414
Guo W et al (2008) Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-Âcell formation. Nature 453(7194):529–533
Hermann PC et al (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1(3):313–323
Holcomb IN et al (2009) Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer. Cancer Res 69(19): 7793–7802
Hubner A et al (2012) JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate. Proc Natl Acad Sci USA 109(30):12046–12051
Iwata T et al (2010) MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells. PLoS One 5(2):e9427
Jeter CR et al (2009) Functional evidence that the self-renewal gene NANOG regulates human tumor development. Stem Cells 27(5):993–1005
Jiao J et al (2012) Identification of CD166 as a Surface Marker for Enriching Prostate Stem/ Progenitor and Cancer Initiating Cells. PLoS One 7(8):e42564
Kamminga LM et al (2006) The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. Blood 107(5):2170–2179
Kasper S, Cookson MS (2006) Mechanisms leading to the development of hormone-resistant prostate cancer. Urol Clin North Am 33(2):201–210, vii
King JC et al (2009) Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 41(5):524–526
Kong D et al (2010) Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS One 5(8):e12445
Kong D et al (2012) Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM. PLoS One 7(3):e33729
Korsten H et al (2009) Accumulating progenitor cells in the luminal epithelial cell layer are candidate tumor initiating cells in a Pten knockout mouse prostate cancer model. PLoS One 4(5):e5662
Lawson DA et al (2007) Isolation and functional characterization of murine prostate stem cells. Proc Natl Acad Sci USA 104(1):181–186
Lawson DA et al (2010) Basal epithelial stem cells are efficient targets for prostate cancer initiation. Proc Natl Acad Sci USA 107(6):2610–2615
Liao CP et al (2010) Cancer-associated fibroblasts enhance the gland-forming capability of prostate cancer stem cells. Cancer Res 70(18):7294–7303
Liu W et al (2009) Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 15(5):559–565
Luchman HA et al (2008) The pace of prostatic intraepithelial neoplasia development is determined by the timing of Pten tumor suppressor gene excision. PLoS One 3(12):e3940
Lukacs RU et al (2010) Bmi-1 is a crucial regulator of prostate stem cell self-renewal and malignant transformation. Cell Stem Cell 7(6):682–693
Ma X et al (2005) Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. Cancer Res 65(13):5730–5739
Maddison LA et al (2000) Prostate specific expression of Cre recombinase in transgenic mice. Genesis 26(2):154–156
Maira SM et al (2008) Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7(7):1851–1863
Mani SA et al (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133(4):704–715
Martin P et al (2011) Prostate epithelial Pten/TP53 loss leads to transformation of multipotential progenitors and epithelial to mesenchymal transition. Am J Pathol 179(1):422–435
Mulholland DJ et al (2009) Lin-Sca-1+ CD49fhigh stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model. Cancer Res 69(22):8555–8562
Mulholland DJ et al (2012) Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res 72(7):1878–1889
Nacerddine K et al (2012) Akt-mediated phosphorylation of Bmi1 modulates its oncogenic potential, E3 ligase activity, and DNA damage repair activity in mouse prostate cancer. J Clin Invest 122(5):1920–1932
Ogata R et al (2004) Identification of polycomb group protein enhancer of zeste homolog 2 (EZH2)-derived peptides immunogenic in HLA-A24+ prostate cancer patients. Prostate 60(4):273–281
Patrawala L et al (2005) Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res 65(14):6207–6219
Patrawala L et al (2006) Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 25(12):1696–1708
Pearson HB, Phesse TJ, Clarke AR (2009) K-ras and Wnt signaling synergize to accelerate prostate tumorigenesis in the mouse. Cancer Res 69(1):94–101
Pece S et al (2010) Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 140(1):62–73
Richardson GD et al (2004) CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 117(Pt 16):3539–3545
Savona M, Talpaz M (2008) Getting to the stem of chronic myeloid leukaemia. Nat Rev Cancer 8(5):341–350
Schlomm T et al (2008) Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol 21(11):1371–1378
Shahi P et al (2011) Wnt and Notch pathways have interrelated opposing roles on prostate progenitor cell proliferation and differentiation. Stem Cells 29(4):678–688
Sircar K et al (2009) PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol 218(4):505–513
Squire JA (2009) TMPRSS2-ERG and PTEN loss in prostate cancer. Nat Genet 41(5):509–510
Stiles BL et al (2006) Selective deletion of Pten in pancreatic beta cells leads to increased islet mass and resistance to STZ-induced diabetes. Mol Cell Biol 26(7):2772–2781
Suva ML et al (2009) EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res 69(24):9211–9218
Tanaka H et al (2010) Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat Med 16(12):1414–1420
Taylor BS et al (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18(1):11–22
Tran CP et al (2002) Prostate stem cell antigen is a marker of late intermediate prostate epithelial cells. Mol Cancer Res 1(2):113–121
Tsujimura A et al (2002) Proximal location of mouse prostate epithelial stem cells: a model of prostatic homeostasis. J Cell Biol 157(7):1257–1265
van Leenders GJ et al (2007) Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. Eur Urol 52(2):455–463
Vander Griend DJ et al (2008) The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res 68(23):9703–9711
Varambally S et al (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419(6907):624–629
Visvader JE, Lindeman GJ (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8(10):755–768
Wang JC (2007) Evaluating therapeutic efficacy against cancer stem cells: new challenges posed by a new paradigm. Cell Stem Cell 1(5):497–501
Wang S et al (2003) Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4(3):209–221
Wang S et al (2006) Pten deletion leads to the expansion of a prostatic stem/progenitor cell Âsubpopulation and tumor initiation. Proc Natl Acad Sci USA 103(5):1480–1485
Wang X et al (2009) A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 461(7263):495–500
Wu X et al (2001) Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev 101(1–2):61–69
Xin L, Lawson DA, Witte ON (2005) The Sca-1 cell surface marker enriches for a prostate-Âregenerating cell subpopulation that can initiate prostate tumorigenesis. Proc Natl Acad Sci USA 102(19):6942–6947
Yilmaz OH et al (2006) Pten dependence distinguishes haematopoietic stem cells from leukaemia-Âinitiating cells. Nature 441(7092):475–482
Zhang J et al (2006) PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 441(7092):518–522
Zhang Q et al (2009) Nuclear factor-kappaB-mediated transforming growth factor-beta-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy. Clin Cancer Res 15(10):3557–3567
Zhou Z et al (2006) Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Res 66(16):7889–7898
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Mulholland, D.J., Wu, H. (2013). Genetic and Signaling Pathway Regulations of Tumor-Initiating Cells of the Prostate. In: Cramer, S. (eds) Stem Cells and Prostate Cancer. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6498-3_5
Download citation
DOI: https://doi.org/10.1007/978-1-4614-6498-3_5
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-6497-6
Online ISBN: 978-1-4614-6498-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)